Preservation of Replaced or Accessory Right Hepatic Artery During Pancreaticoduodenectomy for Adenocarcinoma

Impact on Margin Status and Survival

Olivier Turrini, Eric A. Wiebke, Jean Robert Delpero, Frédéric Viret, Keith D. Lillemoe, C. Schmidt

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Aim: The aim of the study was to determine the impact of replaced or accessory right hepatic artery (RARHA) during pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PA). Methods: Four hundred seventy-one consecutive patients underwent PD for PA at the two institutions; 47 patients (10%) had RARHA: 16 patients (neoRARHA group) received neoadjuvant chemoradiation, and 31 patients did not receive preoperative treatment (RARHA group). Thirty-one matched patients without RARHA comprised our control group. Results: RARHA was preserved in 44 patients; three patients with involved RARHA had reconstruction (n = 2) or ligation (n = 1). Patients with R1 resection (n = 8) had tumor size ≥3 cm. Patients in the neoRARHA group had identical positive margin rate when compared with patients in RARHA group (p = 0.6). No difference was noted in median or 3-year overall survival times between RARHA group and control group. Two patients in RARHA group with involved RARHA died of disease progression after 6 and 12 months of follow-up. One patient in neoRARHA group with involved RARHA was still alive without recurrence after 28 months' follow-up. Conclusions: Pathologic findings did not show increased positive margins despite preservation of RARHA. In contrast, patients with frank RARHA involvement seemed to have poor survival. Thus, patients with suspicion of involved RARHA should be considered for neoadjuvant chemoradiation.

Original languageEnglish
Pages (from-to)1813-1819
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume14
Issue number11
DOIs
StatePublished - 2010

Fingerprint

Pancreaticoduodenectomy
Hepatic Artery
Adenocarcinoma
Survival
Control Groups
Ligation
Disease Progression

Keywords

  • Hepatic artery
  • Margin
  • Neoadjuvant
  • Pancreatic adenocarcinoma
  • Pancreaticoduodenectomy

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Preservation of Replaced or Accessory Right Hepatic Artery During Pancreaticoduodenectomy for Adenocarcinoma : Impact on Margin Status and Survival. / Turrini, Olivier; Wiebke, Eric A.; Delpero, Jean Robert; Viret, Frédéric; Lillemoe, Keith D.; Schmidt, C.

In: Journal of Gastrointestinal Surgery, Vol. 14, No. 11, 2010, p. 1813-1819.

Research output: Contribution to journalArticle

Turrini, Olivier ; Wiebke, Eric A. ; Delpero, Jean Robert ; Viret, Frédéric ; Lillemoe, Keith D. ; Schmidt, C. / Preservation of Replaced or Accessory Right Hepatic Artery During Pancreaticoduodenectomy for Adenocarcinoma : Impact on Margin Status and Survival. In: Journal of Gastrointestinal Surgery. 2010 ; Vol. 14, No. 11. pp. 1813-1819.
@article{57b80cb0fcd34ed0b8786738b0a21051,
title = "Preservation of Replaced or Accessory Right Hepatic Artery During Pancreaticoduodenectomy for Adenocarcinoma: Impact on Margin Status and Survival",
abstract = "Aim: The aim of the study was to determine the impact of replaced or accessory right hepatic artery (RARHA) during pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PA). Methods: Four hundred seventy-one consecutive patients underwent PD for PA at the two institutions; 47 patients (10{\%}) had RARHA: 16 patients (neoRARHA group) received neoadjuvant chemoradiation, and 31 patients did not receive preoperative treatment (RARHA group). Thirty-one matched patients without RARHA comprised our control group. Results: RARHA was preserved in 44 patients; three patients with involved RARHA had reconstruction (n = 2) or ligation (n = 1). Patients with R1 resection (n = 8) had tumor size ≥3 cm. Patients in the neoRARHA group had identical positive margin rate when compared with patients in RARHA group (p = 0.6). No difference was noted in median or 3-year overall survival times between RARHA group and control group. Two patients in RARHA group with involved RARHA died of disease progression after 6 and 12 months of follow-up. One patient in neoRARHA group with involved RARHA was still alive without recurrence after 28 months' follow-up. Conclusions: Pathologic findings did not show increased positive margins despite preservation of RARHA. In contrast, patients with frank RARHA involvement seemed to have poor survival. Thus, patients with suspicion of involved RARHA should be considered for neoadjuvant chemoradiation.",
keywords = "Hepatic artery, Margin, Neoadjuvant, Pancreatic adenocarcinoma, Pancreaticoduodenectomy",
author = "Olivier Turrini and Wiebke, {Eric A.} and Delpero, {Jean Robert} and Fr{\'e}d{\'e}ric Viret and Lillemoe, {Keith D.} and C. Schmidt",
year = "2010",
doi = "10.1007/s11605-010-1272-1",
language = "English",
volume = "14",
pages = "1813--1819",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Preservation of Replaced or Accessory Right Hepatic Artery During Pancreaticoduodenectomy for Adenocarcinoma

T2 - Impact on Margin Status and Survival

AU - Turrini, Olivier

AU - Wiebke, Eric A.

AU - Delpero, Jean Robert

AU - Viret, Frédéric

AU - Lillemoe, Keith D.

AU - Schmidt, C.

PY - 2010

Y1 - 2010

N2 - Aim: The aim of the study was to determine the impact of replaced or accessory right hepatic artery (RARHA) during pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PA). Methods: Four hundred seventy-one consecutive patients underwent PD for PA at the two institutions; 47 patients (10%) had RARHA: 16 patients (neoRARHA group) received neoadjuvant chemoradiation, and 31 patients did not receive preoperative treatment (RARHA group). Thirty-one matched patients without RARHA comprised our control group. Results: RARHA was preserved in 44 patients; three patients with involved RARHA had reconstruction (n = 2) or ligation (n = 1). Patients with R1 resection (n = 8) had tumor size ≥3 cm. Patients in the neoRARHA group had identical positive margin rate when compared with patients in RARHA group (p = 0.6). No difference was noted in median or 3-year overall survival times between RARHA group and control group. Two patients in RARHA group with involved RARHA died of disease progression after 6 and 12 months of follow-up. One patient in neoRARHA group with involved RARHA was still alive without recurrence after 28 months' follow-up. Conclusions: Pathologic findings did not show increased positive margins despite preservation of RARHA. In contrast, patients with frank RARHA involvement seemed to have poor survival. Thus, patients with suspicion of involved RARHA should be considered for neoadjuvant chemoradiation.

AB - Aim: The aim of the study was to determine the impact of replaced or accessory right hepatic artery (RARHA) during pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PA). Methods: Four hundred seventy-one consecutive patients underwent PD for PA at the two institutions; 47 patients (10%) had RARHA: 16 patients (neoRARHA group) received neoadjuvant chemoradiation, and 31 patients did not receive preoperative treatment (RARHA group). Thirty-one matched patients without RARHA comprised our control group. Results: RARHA was preserved in 44 patients; three patients with involved RARHA had reconstruction (n = 2) or ligation (n = 1). Patients with R1 resection (n = 8) had tumor size ≥3 cm. Patients in the neoRARHA group had identical positive margin rate when compared with patients in RARHA group (p = 0.6). No difference was noted in median or 3-year overall survival times between RARHA group and control group. Two patients in RARHA group with involved RARHA died of disease progression after 6 and 12 months of follow-up. One patient in neoRARHA group with involved RARHA was still alive without recurrence after 28 months' follow-up. Conclusions: Pathologic findings did not show increased positive margins despite preservation of RARHA. In contrast, patients with frank RARHA involvement seemed to have poor survival. Thus, patients with suspicion of involved RARHA should be considered for neoadjuvant chemoradiation.

KW - Hepatic artery

KW - Margin

KW - Neoadjuvant

KW - Pancreatic adenocarcinoma

KW - Pancreaticoduodenectomy

UR - http://www.scopus.com/inward/record.url?scp=77958471973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958471973&partnerID=8YFLogxK

U2 - 10.1007/s11605-010-1272-1

DO - 10.1007/s11605-010-1272-1

M3 - Article

VL - 14

SP - 1813

EP - 1819

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 11

ER -